Travere Therapeutics (TVTX) Interest Coverage Ratio Growth (1y) (2012 - 2026)
Travere Therapeutics (TVTX) Interest Coverage Ratio Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | -60.44% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - | -347.04% |
| 4 | BeOne Medicines | 469.11 Bn | 464.32 Bn | 1.35 Bn | 787.12% |
| 5 | Vertex Pharmaceuticals | 123.03 Bn | 115.78 Bn | 2.59 Bn | 53.59% |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.37 Bn | 3.31 Bn | -32.04% |
| 7 | Belite Bio | 63.44 Bn | 63.44 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 1,378.45% |
| 10 | Travere Therapeutics | 5.31 Bn | 5.31 Bn | 125.25 Mn | -9.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.07% |
| Dec 31, 2025 | 89.60% |
| Sep 30, 2025 | 145.19% |
| Jun 30, 2025 | 97.61% |
| Mar 31, 2025 | 70.41% |
| Dec 31, 2024 | -312.04% |
| Sep 30, 2024 | 38.90% |
| Jun 30, 2024 | 34.59% |
| Mar 31, 2024 | -48.11% |
| Dec 31, 2023 | -9.23% |
| Sep 30, 2023 | -11.25% |
| Jun 30, 2023 | -41.83% |
| Mar 31, 2023 | -16.61% |
| Dec 31, 2022 | -427.44% |
| Sep 30, 2022 | -60.48% |
| Jun 30, 2022 | -234.35% |
| Mar 31, 2022 | -170.13% |
| Dec 31, 2021 | -129.88% |
| Sep 30, 2021 | -63.16% |
| Jun 30, 2021 | -46.37% |